Intrathecally administered c-fos antisense oligodeoxynucleotide decreases formalin-induced nociceptive behavior in adult rats

European Journal of Pharmacology

Volumn 329, Issue 1, 1997, Pages 17-26

  Hou, Wen Yeong ^a   Shyu, Bai Chuang ^b   Chen, Tzer Ming ^a   Lee, Jai Wei ^a   Shieh, Jeng Yung ^a   Sun, Wei Zen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Antisense oligodeoxynucleotide; C fos; Formalin test; Hyperalgesia; Intrathecal; Nociception

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FORMALDEHYDE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BITE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HYPERALGESIA; IMMEDIATE EARLY GENE; IMMUNOREACTIVITY; INTRATHECAL DRUG ADMINISTRATION; LICKING; LUMBAR SPINAL CORD; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD DORSAL HORN;

EID: 0031577185     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)10093-0     Document Type: Article

References (43)

1. Abbadie C., Besson J.M. C-fos expression in rat lumbar spinal cord during the development of adjuvant-induced arthritis. Neuroscience. 48:1992;985-993.
2. Abbott F.V., Franklin K.B.J., Westbrook R.F. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain. 60:1995;91-102.
3. Barr G.A., Paredes W., Erickson K., Zukin R.S. Kappa opioid receptor-mediated analgesia in the developing rat. Dev. Brain Res. 29:1986;145-152.
4. Bullitt E. Expression of c-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat. J. Comp. Neurol. 296:1990;517-530.
5. Caudle R.M., Issac L. Influence of dynorphin (1-13) on spinal reflexes in the rat. J. Pharmacol. Exp. Ther. 246:1988;508-513.
6. Chapman V., Buritova J., Honore P., Besson J.M. 7-Nitro-indazole, a selective inhibitor of neuronal nitric oxide synthase reduces formalin evoked c-Fos expression in dorsal horn neurons of the spinal cord. Brain Res. 697:1995;258-261.
7. Chiasson B.J., Hooper M.L., Murphy P.R., Robertson H.A. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmacol. 227:1992;451-453.
8. Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Robertson H.R. The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell. Mol. Neurobil. 14(5):1994;507-521.
9. Chien C.C., Brown G., Pan Y.X., Pastenak G.W. Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor. Eur. J. Pharmacol. 253:1994;R7-R8.
10. Coderre T.G., Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J. Neurosci. 12(9):1992;3665-3675.
11. Draisci G., Iadarola M.J. Temporal analysis of increases in c-fos gene, preprodynorphin and preproenkephalin mRNAs in rats spinal cord. Mol. Brain Res. 6:1989;31-37.
12. Dubner R., Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15:1992;96-101.
13. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesia effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
14. Gillardon F., Beck H., Uhlmann E., Herdegen T., Sandkuhler J., Peyman A., Zimmermann M. Inhibition of c-Fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion. Eur. J. Neurosci. 6:1994;880-884.
15. Gogas K.R., Presley R.W., Leving J.D., Basbaum A.I. The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: correlation of nociceptive behavior and c-fos expression. Neuroscience. 42:1991;617-628.
16. Greenberg M.E., Greene L.A., Ziff E.B. Nerve growth factor and epidermal growth factor induce rapid transient changes in proto-oncogene transcription in PC12 cells. J. Biol. Chem. 260:1985;14101-14110.
17. Heapy C.G., Jamieson A., Russell N.J.W. Afferent C-fibre and A-delta activity in models of inflammation. Br. J. Pharmacol. 90:1987;164P.
18. Herdegen T., Kovary K., Leah J., Bravo R. Specific temporal and spatial distribution of Jun, Fos, and Krox-24 proteins in spinal neurons following noxious transsynaptic stimulation. J. Comp. Neurol. 313:1991;178-191.
19. Honore P., Chapman V., Buritova J., Besson J.M. When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? Brain Res. 705:1995;91-96.
20. Hooper M.L., Chiasson B.J., Robertson H.A. Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of Fos and produces a behavioral effect. Neuroscience. 63:1994;917-924.
21. Hunt S.P., Pini A., Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;632-634.
22. Hunter J.C., Woodburn V.L., Durieux C., Pettersson E.J.E., Poat J.A., Hughes J. C-fos antisense oligodeoxynucleotide increases formalin-induced nociception and regulates preprodynorphin expression. Neuroscience. 2:1995;485-492.
23. Hylden J.L.K., Nahin R.L., Traub R.J., Dubner R. Effects of spinal kappa-opioid receptors agonists on the responsiveness of nociceptive superficial dorsal horn neurons. Pain. 44:1991;187-193.
24. Iadorola M.J., Douglass J., Civelli O., Naranjo J.R. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization. Brain Res. 455:1988;205-212.
25. Jackson H.C., Kitchen I. Behavioural effects of selective mu, kappa, and delta opioid agonist in neonatal rats. Psychopharmacology. 97:1989;404-409.
26. Kehl, L.J., Gogas, K.R., Lichtblau, L., Pollack, C.H., Mayes, M., Basbaum, A.I., Wilcox, G.L., 1991. The NMDA antagonist MK-801 reduces noxious stimulus-evoked Fos expression in the spinal dorsal horn. In: Bond, M.R., Charlton, J.R., Woolf, C.J. (Eds.), Pain Research and Clinical Management, Vol. 4, Proc. VIth World Congress on Pain. Elsevier, Amsterdam, pp. 307-311.
27. Kindy, M.S., Verma, I.M., 1988. Inhibition of c-fos gene expression does not alter the differentiation pattern of PC 12 cells. In: Melton, D.A. (Ed.), Antisense RNA and DNA. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 129-133.
28. Massardier D., Hunt P.F. A direct non-opioid interaction of dynorphin (1-13) with the N-methyl-D-aspartate (NMDA) receptor. Eur. J. Pharmacol. 170:1989;125-126.
29. Molander C., Xu Q., Grant G. The cytoarchitectonic organization of the spinal cord in the rat. I. The lower thoracic and lumbosacral cord J. Comp. Neurol. 230:1984;133-141.
30. Munglani E., Berrebi A.S., Morgan J.I., Curran T. Fos-like immunoreactivity induced by seizure in mice is specifically associated with euchromatin in neurons. Eur. J. Neurosci. 1:1989;46-52.
31. Naranjo J.R., Mellstrom B., Achaval M., Sassone-Corsi P. Molecular pathway of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron. 6:1991;607-617.
32. Necker L., Whitesell L. Antisense technology: biological utility and practical considerations. Am. J. Physiol. 265:1993;L1-L12.
33. Noguchi K., Kowalski K., Traub R., Solodkin A., Iadarola M.J., Ruda M.A. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Mol. Brain Res. 10:1991;227-233.
34. Presley R.W., Menetrey D., Levine J.D., Basbaum A.I. Systemic morphine suppresses noxious stimulation evoked Fos protein-like immunoreactivity in the rat spinal cord. J. Neurosci. 10:1990;323-335.
35. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science. 240:1988;1328-1331.
36. Skilling S.R., Sun X., Kurtz H.J., Larson A.A. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: possible roles in paralysis and neurotoxicity. Brain Res. 575:1992;272-278.
37. Standifer K.M., Fenab S., Su W., Chien C.C., Pan Y.X., Inturrisi C.E., Pasternak G.W. Antisense oligodeoxynucleotides to the cloned delta receptor DOR-1: uptake, stability, and regulation of gene expression. J. Neurochem. 645:1995;1981-1986.
38. Sun W.Z., Shyu B.C., Shieh J.Y. Nitrous oxide or halothane, or both, fail to suppress c-fos expression in rat spinal cord dorsal horn neurones after subcutaneous formalin. Br. J. Anaesth. 76:1996;99-105.
39. Wahlestedt C. Antisense oligonucleotides strategies in neuropharmacology. Trends Pharmacol. Sci. 15:1994;42-46.
40. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis D.J. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduced focal ischemic infarctions. Nature. 363:1993;260-264.
41. Wahlestedt C., Pich E.M., Koob G.F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
42. Wheeler-Aceto H., Porreca F., Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology. 104:1991;35-44.
43. White J.D., Gall C.M. Differential regulation of neuropeptide and proto-oncogene mRNA content in the hippocampus following recurrent seizure. Mol. Brain Res. 3:1987;21-29.